Extended Data Table 4 Curated signatures representing potential clinically relevant pathways and immune subsets identified from genome-wide DEG, GESA and xCell analyses

From: Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

  1. *DEG, differentially expressed genes (two-sided P < 0.05 and FC > 1) responders versus nonresponders in patients from GO30140 group A and IMbrave150 group atezolizumab + bevacizumab.
Back to article page